Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Tuesday, Analyst Ratings Network reports.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
A number of other analysts have also recently weighed in on BMY. Analysts at Morgan Joseph upgraded shares of Bristol-Myers Squibb (NYSE:BMY) from a “neutral” rating to an “overweight” rating in a research note to investors on Monday. They now have a $52.00 price target on the stock, up previously from $50.00. Separately, analysts at JPMorgan Chase & Co. upgraded shares of Bristol-Myers Squibb (NYSE:BMY) from a “neutral” rating to an “overweight” rating in a research note to investors on Monday. They now have a $52.00 price target on the stock, up previously from $50.00. Finally, analysts at Jefferies Group cut their price target on shares of Bristol-Myers Squibb (NYSE:BMY) from $45.00 to $41.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Buy” and a consensus price target of $46.36.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.09% during mid-day trading on Tuesday, hitting $45.18. 1,733,270 shares of the company’s stock traded hands. Bristol-Myers Squibb has a 52 week low of $30.64 and a 52 week high of $49.57. The stock’s 50-day moving average is $42.75 and its 200-day moving average is $42.70. The company has a market cap of $74.381 billion and a price-to-earnings ratio of 55.12.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.45 by $0.01. The company had revenue of $4.05 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was down 8.9% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.74 EPS for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.